Search

Diffuse large B-cell lymphoma is an aggressive disease occurring primarily in elderly patients. Despite high curative rates with doxorubicin-containing treatment, some elderly patients receive less intensive treatments, mainly due to advanced age, comorbidities, and concerns of cardiotoxicity from doxorubicin-containing regimens. We analyzed 1009 patients aged 75 years or older and 10,090 age- and sex-matched comparisons. We aimed to evaluate long-term cardiovascular side effects in elderly patients treated with doxorubicin. Approximately, 64% of patients received doxorubicin-containing treatment. These patients had a persistently increased risk of new-onset heart failure with a hazard ratio of 1.5 and 1.7 when conditioning on survival without heart failure to 6 and 24 months, respectively. Moreover, we observed an increased risk of venous thromboembolism during the first six months following the lymphoma diagnosis. On the contrary, no difference in risk of developing ischemic heart disease or stroke following doxorubicin-containing treatment was observed. [ABSTRACT FROM AUTHOR]

Highlights from the article: Xanthougranulomatous inflammation is a rare condition, thought to be caused by chronic inflammation, and is pathologically characterized by multinucleated giant cells, polymorphonuclear plasma cells and lipid-laden macrophages (xanthoma cells). In previous reports, medical or conservative treatment with antibiotics is generally reported as insufficient treatment of xanthogranulomatosis. As the tumor in this case was benign, it was thought reasonable to try medical treatment before offering extensive surgery with a considerable risk of complications, although steroid based therapy is not evidence-based.